An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC

Status: Open to Accrual

Learn more:

• https://clinicaltrials.gov/study/NCT03909334
• See news release

Abstracts/Posters/Presentations:

• A. Saltos, C. Baik, R.E. Sanborn, E. Shum, C. Kim, R. Hall, M.J. Fidler, C.A. Shu, G. Otterson, J. Patel, K.K. Wong, N. Hanna, J. Gray, J. Heymach, X. Le. RAMOSE: An Open-Label Randomized Phase II Study of Osimertinib with or without Ramucirumab in TKI-naïve EGFR-mutant Metastatic NSCLC. Presented at the IASLC 2020 World Conference on Lung Cancer. See abstract.

Study Contact: studies@hoosiercancer.org; (317) 921-2050.